Peptides

Tesamorelin

Targeted visceral-fat and body-composition support for appropriately selected individuals.

Common goals: Clinically demonstrated reduction in visceral abdominal fat for adults with HIV-associated lipodystrophy.
Best program fit: May fit condition-specific programs that can measure waist, imaging, glucose, IGF-1, and function.
Format: Clinician-confirmed formulation

Partner education guide

Where this may fit in an offering.

Clinically demonstrated reduction in visceral abdominal fat for adults with HIV-associated lipodystrophy. Potential reduction in waist or abdominal-fat burden while overall body weight may remain relatively stable. Offers a targeted option for a specific, difficult-to-treat fat-distribution problem.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

Clinically demonstrated reduction in visceral abdominal fat for adults with HIV-associated lipodystrophy.
Potential reduction in waist or abdominal-fat burden while overall body weight may remain relatively stable.
May improve selected triglyceride and body-composition measures in appropriately selected individuals.

Program value

How it may support a program

Offers a targeted option for a specific, difficult-to-treat fat-distribution problem.
Provides measurable follow-up through waist, imaging, glucose, IGF-1, and individual-reported function.

Approved benefits apply to the labeled HIV-associated lipodystrophy population and formulation. Results vary, are not guaranteed, and broader weight-loss or wellness use requires separate evidence.

02 / Program fit

Program and operational considerations.

01Administration: Catalog format: Clinician-confirmed formulation. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency: The current EGRIFTA WR label specifies 1.28 mg once daily. Product-specific concentration and reconstitution instructions matter.
03Expected duration: Treatment is reassessed over months using visceral-fat or waist outcomes, metabolic safety, IGF-1, and ongoing clinical need. Fat can return after discontinuation.
04Practical advantages: Offers a targeted option for a specific, difficult-to-treat fat-distribution problem.

03 / Suitability considerations

Who may be considered.

Who may be considered

A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

Offers a targeted option for a specific, difficult-to-treat fat-distribution problem.
Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

Common or temporary

Arthralgia, injection-site redness or itching, limb pain, peripheral edema, and muscle pain occur in more than 5% of treated individuals in label data.
Fluid retention may produce swelling, joint discomfort, or carpal-tunnel-type symptoms.

Serious or important

Tesamorelin can raise IGF-1 and may cause or worsen glucose intolerance or diabetes.
Serious hypersensitivity can occur. Active malignancy is a contraindication, and recurrence risk requires careful review because growth-hormone signaling is increased.
Long-term cardiovascular safety is not established.

Avoid or use only with specialist input

Pregnancy, active malignancy, serious hypersensitivity to tesamorelin or excipients, or disruption of the hypothalamic-pituitary axis from tumor, surgery, radiation, trauma, hypophysectomy, or hypopituitarism.
General weight-loss treatment or use in children and adolescents outside specialist care.

Screening checklist

Confirm HIV status, lipodystrophy phenotype, medicines and antiretroviral plan, cancer history, pituitary history, pregnancy status, fasting glucose or A1c, retinal disease when diabetes is present, and baseline IGF-1.
Document waist or imaging-based visceral-fat measures when clinically appropriate and monitor IGF-1, glucose, edema, joint or nerve symptoms, and injection sites.

When to refer

HIV management should remain coordinated with an HIV specialist. Abnormal IGF-1, active or recurrent cancer, pituitary disease, worsening glucose, visual symptoms, or serious allergy requires appropriate specialist or urgent medical care.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

Multiple randomized trials support one narrow individual group, not broad wellness use.

01 / Human research

The clearest clinical signal

Several randomized trials show less deep belly fat in people with HIV-associated lipodystrophy. This is not proof for general weight loss or anti-aging.

02 / Real-world reports

What people describe

About eight detailed accounts were sampled, mostly from body-composition communities rather than HIV care. Users described waist change after 1-3 months; others saw no loss.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Injection reactions, headache, flushing, swelling, joint or nerve pain, and higher blood sugar may occur. Growth signals can raise IGF-1. Long-term cancer and heart safety for wellness use are not known.

Does the research match this exact product?

The catalog does not state the studied 2 mg daily injection or HIV indication.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Download the evidence briefPDF · larger type

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments